S&P 500   4,550.77 (+0.40%)
DOW   35,156.19 (+0.36%)
QQQ   369.13 (+0.72%)
AAPL   166.84 (+0.37%)
MSFT   307.21 (+1.28%)
FB   322.59 (+0.94%)
GOOGL   2,724.07 (+0.80%)
AMZN   3,110.52 (-0.49%)
TSLA   1,021.24 (+2.57%)
NVDA   251.71 (+0.41%)
BABA   132.62 (+3.82%)
NIO   30.08 (+5.06%)
AMD   126.97 (-1.01%)
CGC   7.77 (+1.70%)
MU   88.04 (-2.18%)
GE   100.32 (-0.30%)
T   27.29 (+0.04%)
F   22.14 (-1.38%)
DIS   150.33 (+0.15%)
AMC   19.04 (+3.93%)
PFE   54.11 (+1.06%)
ACB   4.87 (+0.21%)
BA   218.36 (+0.59%)
S&P 500   4,550.77 (+0.40%)
DOW   35,156.19 (+0.36%)
QQQ   369.13 (+0.72%)
AAPL   166.84 (+0.37%)
MSFT   307.21 (+1.28%)
FB   322.59 (+0.94%)
GOOGL   2,724.07 (+0.80%)
AMZN   3,110.52 (-0.49%)
TSLA   1,021.24 (+2.57%)
NVDA   251.71 (+0.41%)
BABA   132.62 (+3.82%)
NIO   30.08 (+5.06%)
AMD   126.97 (-1.01%)
CGC   7.77 (+1.70%)
MU   88.04 (-2.18%)
GE   100.32 (-0.30%)
T   27.29 (+0.04%)
F   22.14 (-1.38%)
DIS   150.33 (+0.15%)
AMC   19.04 (+3.93%)
PFE   54.11 (+1.06%)
ACB   4.87 (+0.21%)
BA   218.36 (+0.59%)
S&P 500   4,550.77 (+0.40%)
DOW   35,156.19 (+0.36%)
QQQ   369.13 (+0.72%)
AAPL   166.84 (+0.37%)
MSFT   307.21 (+1.28%)
FB   322.59 (+0.94%)
GOOGL   2,724.07 (+0.80%)
AMZN   3,110.52 (-0.49%)
TSLA   1,021.24 (+2.57%)
NVDA   251.71 (+0.41%)
BABA   132.62 (+3.82%)
NIO   30.08 (+5.06%)
AMD   126.97 (-1.01%)
CGC   7.77 (+1.70%)
MU   88.04 (-2.18%)
GE   100.32 (-0.30%)
T   27.29 (+0.04%)
F   22.14 (-1.38%)
DIS   150.33 (+0.15%)
AMC   19.04 (+3.93%)
PFE   54.11 (+1.06%)
ACB   4.87 (+0.21%)
BA   218.36 (+0.59%)
S&P 500   4,550.77 (+0.40%)
DOW   35,156.19 (+0.36%)
QQQ   369.13 (+0.72%)
AAPL   166.84 (+0.37%)
MSFT   307.21 (+1.28%)
FB   322.59 (+0.94%)
GOOGL   2,724.07 (+0.80%)
AMZN   3,110.52 (-0.49%)
TSLA   1,021.24 (+2.57%)
NVDA   251.71 (+0.41%)
BABA   132.62 (+3.82%)
NIO   30.08 (+5.06%)
AMD   126.97 (-1.01%)
CGC   7.77 (+1.70%)
MU   88.04 (-2.18%)
GE   100.32 (-0.30%)
T   27.29 (+0.04%)
F   22.14 (-1.38%)
DIS   150.33 (+0.15%)
AMC   19.04 (+3.93%)
PFE   54.11 (+1.06%)
ACB   4.87 (+0.21%)
BA   218.36 (+0.59%)
NASDAQ:ARVN

Arvinas Stock Forecast, Price & News

$67.29
+2.87 (+4.46%)
(As of 01/20/2022 02:24 PM ET)
Add
Compare
Today's Range
$65.26
$68.15
50-Day Range
$64.42
$85.67
52-Week Range
$56.59
$108.46
Volume
14,084 shs
Average Volume
294,272 shs
Market Capitalization
$3.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.93
30 days | 90 days | 365 days | Advanced Chart
Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.


Arvinas logo

About Arvinas

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Headlines

Arvinas (NASDAQ:ARVN) Shares Gap Up to $64.61
January 19, 2022 |  americanbankingnews.com
Arvinas (NASDAQ:ARVN) Now Covered by The Goldman Sachs Group
January 19, 2022 |  americanbankingnews.com
Should I Avoid Arvinas, Inc. (ARVN)?
December 12, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
179
Year Founded
N/A

Sales & Book Value

Annual Sales
$21.80 million
Book Value
$13.27 per share

Profitability

Net Income
$-119.33 million
Net Margins
-794.97%
Pretax Margin
-794.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
49,462,000
Market Cap
$3.56 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/20/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

343rd out of 1,415 stocks

Pharmaceutical Preparations Industry

159th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas
or view top-rated stocks.

How has Arvinas' stock price been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 52.7% and is now trading at $67.29.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in December. As of December 15th, there was short interest totaling 2,430,000 shares, an increase of 38.9% from the November 30th total of 1,750,000 shares. Based on an average daily volume of 402,300 shares, the days-to-cover ratio is currently 6.0 days. Approximately 5.5% of the shares of the stock are short sold.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $2.13 by $3.07. The business earned $9.28 million during the quarter, compared to the consensus estimate of $26.89 million. Arvinas had a negative net margin of 794.97% and a negative trailing twelve-month return on equity of 27.02%. The company's revenue for the quarter was up 22.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.79) EPS.
View Arvinas' earnings history
.

What price target have analysts set for ARVN?

15 brokers have issued twelve-month target prices for Arvinas' shares. Their forecasts range from $108.00 to $170.00. On average, they anticipate Arvinas' share price to reach $130.54 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price.
View analysts' price targets for Arvinas
or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.16%), Joel Isaacson & Co. LLC (0.09%), Polianta Ltd (0.03%), Endurance Wealth Management Inc. (0.00%), Cutler Group LP (0.00%) and Lindbrook Capital LLC (0.00%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas
.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Joel Isaacson & Co. LLC, and Endurance Wealth Management Inc.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or view top insider-selling stocks.

Which major investors are buying Arvinas stock?

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and Lindbrook Capital LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $67.29.

How much money does Arvinas make?

Arvinas has a market capitalization of $3.56 billion and generates $21.80 million in revenue each year. The company earns $-119.33 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 179 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.